Dataset Information

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

ABSTRACT: Cancer immunotherapy based on antibodies targeting the immune checkpoint PD-1/PD-L1 pathway has seen unprecedented clinical responses and constitutes the new paradigm in cancer therapy. The antibody-based immunotherapies have several limitations such as high production cost of the antibodies or their long half-life. Small-molecule inhibitors of the PD-1/PD-L1 interaction have been highly anticipated as a promising alternative or complementary therapeutic to the monoclonal antibodies (mAbs). Currently, the field of developing anti-PD-1/PD-L1 small-molecule inhibitors is intensively explored. In this paper, we review anti-PD-1/PD-L1 small-molecule and peptide-based inhibitors and discuss recent structural and preclinical/clinical aspects of their development. Discovery of the therapeutics based on small-molecule inhibitors of the PD-1/PD-L1 interaction represents a promising but challenging perspective in cancer treatment.

SUBMITTER: Guzik K

PROVIDER: S-EPMC6600339 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Guzik Katarzyna K Tomala Marcin M Muszak Damian D Konieczny Magdalena M Hec Aleksandra A Błaszkiewicz Urszula U Pustuła Marcin M Butera Roberto R Dömling Alexander A Holak Tad A TA

Molecules (Basel, Switzerland) 20190530 11

Cancer immunotherapy based on antibodies targeting the immune checkpoint PD-1/PD-L1 pathway has seen unprecedented clinical responses and constitutes the new paradigm in cancer therapy. The antibody-based immunotherapies have several limitations such as high production cost of the antibodies or their long half-life. Small-molecule inhibitors of the PD-1/PD-L1 interaction have been highly anticipated as a promising alternative or complementary therapeutic to the monoclonal antibodies (mAbs). Curr ...[more]

PMID: 31151293

Dataset Information

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Publications

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).
| S-EPMC6323140 | biostudies-literature

The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules.
| S-EPMC6572691 | biostudies-literature

High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.
| S-EPMC6113430 | biostudies-literature

[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
| S-EPMC6580087 | biostudies-literature

PD-L1 inhibitors in the pipeline: Promise and progress.
| S-EPMC5739559 | biostudies-literature

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.
| S-EPMC7080697 | biostudies-literature

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.
| S-EPMC5870495 | biostudies-literature

Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy.
| S-EPMC8770281 | biostudies-literature

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules.
| S-EPMC10974325 | biostudies-literature

[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
| S-EPMC6712270 | biostudies-literature